News Press Releases

REGENXBIO to Participate in Upcoming Investor Conferences

RGNX | March 6, 2019

PR Newswire

ROCKVILLE, Md., March 6, 2019

ROCKVILLE, Md., March 6, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV^® Technology Platform, today announced that it will participate in the following March investor conferences:

Barclays Global Healthcare Conference
Date: Wednesday, March 13, 2019
Location: Loews Miami Beach Hotel, Miami, FL
Fireside chat: Wednesday, March 13, 2019 at 2:35 p.m. ET

Morgan Stanley Healthcare Corporate Access Day
Date: Tuesday, March 19, 2019
Location: Boston Harbor Hotel at Rowes Wharf, Boston, MA

A live webcast of the Barclays fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available on the same website for approximately 30 days following the presentation. In addition, REGENXBIO senior management will be holding one-on-one meetings at each of the conferences.

About REGENXBIO

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV^® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

CONTACT:

Investors:
Heather Savelle, 212-600-1902
heather@argotpartners.com

Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com

(PRNewsfoto/REGENXBIO Inc.)